Market Intel: 3D Bioprinting Forges Ahead With Mini Human Heart, Human Tissue
Can Bioprinting Become The Future Alternative To Organ Donation?
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.
You may also be interested in...
MD&M BIOMEDigital 2021: ‘There is No Easy Button On 3D Printing,’ Panelist Says
As medical organizations such as the VHA and Mayo Clinic are positioning themselves to become medical device manufacturers using 3D printing technologies, it opens opportunities and challenges.
Market Intel: Cornea, Bio-Drugs, Artificial Hips On Track For 3D Printing
Although certainly not a given, many researchers and companies are pursing the eventual goal of bioprinting human organs, starting with the three-dimensional printing of a structure that has cellular function. If organ function via bioprinting becomes a reality for the skin, bone, lung, liver, eye and/or kidney, among other potential organs, the market opportunity could be in the billions. But challenges, including cost and ethics, stand in the way of this milestone in regenerative medicine.
Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval
Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.